On Tuesday, Shares of Annaly Capital Administration, Inc. (NYSE:NLY), subtract -3.09% and closed at $10.05 in the last trading session. The last trading range of the stock ranges between $10.02 and $10.36. Annaly Capital Administration, Inc. owns a portfolio of real estate related investments in the United States. It invests in various types of agency mortgage-backed securities and related derivatives to hedge these investments; and residential credit investments, such as credit risk transfer securities and non-agency mortgage-backed securities. The company also acquires, finances, and manages commercial loans and other commercial real estate debt, commercial mortgage-backed securities, and other commercial real estate-related assets. In addition, it engages in corporate middle market lending transactions; and operates as a broker-dealer.
AstraZeneca plc (ADR)(NYSE:AZN), dropped -1.30% and closed at $32.57 in the last trading session. The last trading range of the stock ranges between $32.33 and $33.27. The company’s Market capitalization is $82.01 Billion with the total Outstanding Shares of 1.26 Billion. AstraZeneca recently declared that the US Food and Drug Administration (FDA) has approved a blood-based companion diagnostic for TAGRISSO® (osimertinib). The companion diagnostic for TAGRISSO is the only FDA-approved and clinically validated companion diagnostic test that uses either tissue or a blood sample to confirm the presence of a T790M mutation in patients with metastatic epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC), who have progressed on or after an EGFR tyrosine kinase inhibitor (TKI) medicine.
The approval provides a new, non-invasive option to identify patients with metastatic EGFR T790M mutation-positive NSCLC, ensuring that those patients who may not be suitable for biopsy procedures have an opportunity to be tested. Blood-based testing for the presence of the mutation is recommended only when a tumor biopsy cannot be obtained. Patients who test negative for the T790M mutation with the blood-based test, and their physicians, should re-evaluate the feasibility of tissue-based testing to confirm the presence of the EGFR T790M mutation.
Novo Nordisk A/S (ADR)(NYSE:NVO), lost -1.19% and closed at $40.63 in the last trading session. The last trading range of the stock ranges between $40.37 and $40.85. During the 52-week trading session the minimum price at which share price traded, registered at $40.37 and reached to max level of $40.85. Novo Nordisk A/S, a healthcare company, engages in the discovery, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity Care, and Biopharmaceuticals. The Diabetes and Obesity Care segment provides insulins, GLP-1 analog, obesity, and oral antidiabetic drugs, in addition to other protein related products comprising glucagon, protein related delivery systems, and needles. The Biopharmaceuticals segment offers products in the areas of haemophilia care, growth hormone therapy, and hormone replacement therapy. The company markets and distributes its products through distributors and independent agents in North America, Europe, Japan and South Korea, China, Hong Kong, Taiwan, and other countries.